23-Jan-2026 11:53 AM CST - Yahoo Finance Why Analysts See Merck (MRK) Differently After The Latest Price Target Reset The latest update to the Merck stock story centers on a revised price target, reflecting how analysts are reassessing the company based on the most recent information available. This shift in expectations highlights how fresh data and evolving views on the business can influence what some see as a reasonable price level for the shares.
21-Jan-2026 6:00 AM CST - Yahoo Finance Merck & Co (MRK) to Generate $70 Billion in Revenue from Emerging Businesses By Mid-2030s With competition rising to the company's cancer therapy Keytruda, Merck & Co., Inc. (NYSE:MRK) is setting itself up for long-term growth. On January 12, 2026, the company raised its outlook for new growth drivers. Accordingly, Merck projects $70 billion ...
20-Jan-2026 2:46 PM CST - Yahoo Finance Merck (MRK) Builds Post-Keytruda Growth Plan, BMO Upgrades to Outperform Merck & Co. Inc. (NYSE:MRK) ranks among the most active blue chip stocks to buy now. With a raised price target of $130 per share, BMO Capital Markets upgraded Merck & Co. Inc. (NYSE:MRK) to Outperform on December 18,
20-Jan-2026 9:06 AM CST - Yahoo Finance Is Merck's Guardant Liquid Biopsy Alliance Reshaping the Investment Case for MRK? Guardant Health recently announced a multi-year collaboration with Merck to use its Guardant Infinity Smart liquid and tissue biopsy platform to support Merck's global oncology clinical trials, potential companion diagnostics,
12-Jan-2026 6:02 PM CST - Reuters Merck says new growth opportunities to drive revenue of $70 billion by mid-2030s Merck said on Monday it has raised its outlook for new growth drivers, forecasting $70 billion in revenue from these fresh businesses by the mid-2030s, as it accelerates the launch of additional drugs ahead of looming competition to its blockbuster cancer therapy Keytruda.
8-Jan-2026 5:51 PM CST - Yahoo Finance Wells Fargo Adds Merck (MRK) to Q1 2026 Tactical List Ahead of Key Catalysts Merck & Co., Inc. (NYSE:MRK) is included among the 12 Best DOW Stocks to Buy in 2026. On January 5, Wells Fargo added Merck & Co., Inc. (NYSE:MRK) to its Q1 2026 Tactical Ideas List. Wells said Merck is moving into what it calls a catalyst-rich stretch across FY26 and 2027.
Latest MRK Trades by Congress Members
18-NOV-2025 - Gilbert Cisneros, CA (District 31) purchased between $1,001 and $15,000.
23-Jan-2026 11:53 AM CST - Yahoo Finance Why Analysts See Merck (MRK) Differently After The Latest Price Target Reset The latest update to the Merck stock story centers on a revised price target, reflecting how analysts are reassessing the company based on the most recent information available. This shift in expectations highlights how fresh data and evolving views on the business can influence what some see as a reasonable price level for the shares.
21-Jan-2026 6:00 AM CST - Yahoo Finance Merck & Co (MRK) to Generate $70 Billion in Revenue from Emerging Businesses By Mid-2030s With competition rising to the company's cancer therapy Keytruda, Merck & Co., Inc. (NYSE:MRK) is setting itself up for long-term growth. On January 12, 2026, the company raised its outlook for new growth drivers. Accordingly, Merck projects $70 billion ...
20-Jan-2026 2:46 PM CST - Yahoo Finance Merck (MRK) Builds Post-Keytruda Growth Plan, BMO Upgrades to Outperform Merck & Co. Inc. (NYSE:MRK) ranks among the most active blue chip stocks to buy now. With a raised price target of $130 per share, BMO Capital Markets upgraded Merck & Co. Inc. (NYSE:MRK) to Outperform on December 18,
20-Jan-2026 9:06 AM CST - Yahoo Finance Is Merck's Guardant Liquid Biopsy Alliance Reshaping the Investment Case for MRK? Guardant Health recently announced a multi-year collaboration with Merck to use its Guardant Infinity Smart liquid and tissue biopsy platform to support Merck's global oncology clinical trials, potential companion diagnostics,
12-Jan-2026 6:02 PM CST - Reuters Merck says new growth opportunities to drive revenue of $70 billion by mid-2030s Merck said on Monday it has raised its outlook for new growth drivers, forecasting $70 billion in revenue from these fresh businesses by the mid-2030s, as it accelerates the launch of additional drugs ahead of looming competition to its blockbuster cancer therapy Keytruda.
8-Jan-2026 5:51 PM CST - Yahoo Finance Wells Fargo Adds Merck (MRK) to Q1 2026 Tactical List Ahead of Key Catalysts Merck & Co., Inc. (NYSE:MRK) is included among the 12 Best DOW Stocks to Buy in 2026. On January 5, Wells Fargo added Merck & Co., Inc. (NYSE:MRK) to its Q1 2026 Tactical Ideas List. Wells said Merck is moving into what it calls a catalyst-rich stretch across FY26 and 2027.
